Sources of Long-Term Quality Adjusted Life Year (QALY) Gains for Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
Abstract
Authors
I. Girod M. Willis P. Johansen M. Schroeder G. Thompson C. Neslusan